CARGO Therapeutics (CRGX) Q4 2024 earnings summary

Executive summary

• Suspended development of CRG-023 and allogeneic platform; 90% workforce reduction to preserve cash and maximize shareholder value.

• Appointed Anup Radhakrishnan as interim CEO to pursue a reverse merger or other business combination.

• Engaged TD Cowen as exclusive strategic financial advisor for ongoing evaluation of strategic options.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $368.1 million as of December 31, 2024.

Outlook and guidance

• Board aims to maximize shareholder value by ceasing development operations and seeking a business combination or asset sale.

• Priority is to find a permanent home for remaining assets and execute the transition expeditiously.